0 items - $0.00

Major Publications

 

Major Publications using our products

 

 

ELISA using affinity-purified goat anti-human apoCIII antibodies

Edward A Ruiz-Narva´ez, Frank M Sacks, and Hannia Campos; Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction; Am J Clin Nutr 2008;87:1932– 8.

 


 

Goat anti–human apoC-III affinity column, affinity-purified antibodies and HRP conjugated antibodies to apo B, apo C-III, and apo E were applied in this study

Jeremy D Furtado, Hannia Campos, Lawrence J Appel, Edgar R Miller, Nancy Laranjo, Vincent J Carey, and Frank M Sacks; Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial; Am J Clin Nutr 2008;87:1623-30.

 


 

Affinity-purified goat anti-nitrotyrosine polyclonal antibody was used to immobilize antibody column

Melissa R. Radabaugh, Olga V. Nemirovskiy, Thomas P. Misko, Poonam Aggarwal, W. Rodney Mathews; Immunoaffinity liquid chromatography�tandem mass spectrometry detection of nitrotyrosine in biological fluids: Development of a clinically translatable biomarker; Analytical Biochemistry 380 (2008) 68�76

 


 

Ox-LDL, MDA modified LDL, and MDA modified apoB-100 were applied in this study

Alexandru Schiopu, Björn Frendéus, Bo Jansson, Ingrid Söderberg, Irena Ljungcrantz, Zufan Araya, Prediman K. Shah, Roland Carlsson, Jan Nilsson, Gunilla Nordin Fredrikson; Recombinant Antibodies to an Oxidized Low-Density Lipoprotein Epitope Induce Rapid Regression of Atherosclerosis in Apobec-1-/- Low-Density Lipoprotein Receptor-/- Mice; Journal of the American College of Cardiology Vol. 50, No. 24, 2007.

 


 

Ox-LDL, MDA modified LDL, and MDA modified apoB-100 were applied in this study

Jan Nilsson, Gunilla Nordin Fredrikson, Alexandru Schiopu, Prediman K. Shah, Bo Jansson and Roland Carlsson; Oxidized LDL Antibodies in Treatment and Risk Assessment of Atherosclerosis and Associated Cardiovascular Disease; Current Pharmaceutical Design, 2007, 13, 1021-1030.

 


 

 

1 2 3 5